Psychiatr. pro Praxi, 2009; 10(4): 171-174

Adherence and patient’s attitudes to antipsychotic medication

doc. MUDr. Radovan Přikryl Ph.D, PhDr. Hana Kučerová, Ph.D
Psychiatrická klinika LF MU a FN Brno

Adherence to antipsychotic medications in schizophrenia continues to be a significant in terms of its impact on the rate of relapse.

Over the past 50 years, antipsychotic medications have emerged as the cornerstone in the management of the varied symptoms of

schizophrenia. However, the unrivalled role of first-generation antipsychotic medications was continuously challenged because of the

wide range of side-effects. Prominent among these effects were the lack of subjective tolerability and the negative attitudes towards

medications. Neuroleptic-drug-induced dysphoria has been shown to affect compliance behaviour, clinical outcome and quality of life,

and to contribute to suicidal behaviour. Although there is agreement that second-generation antipsychotics are much better tolerated

than the old antipsychotics, there is a need for well-designed comparative studies to explore their effects on adherence behaviour.

Currently available data can only suggest that there is a trend towards improved adherence, functional state and quality of life with the

use of second-generation antipsychotics.

Keywords: adherence, attitudes towards treatment, compliance, schizophrenia.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Přikryl R, Kučerová H. Adherence and patient’s attitudes to antipsychotic medication. Psychiatr. praxi. 2009;10(4):171-174.
Download citation

References

  1. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medications: what are they and are they being achieved? CNS Drugs 1995; 4: 8-16. Go to original source...
  2. Van Putten T, May DRA, Marder SR. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190. Go to original source... Go to PubMed...
  3. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609-618. Go to original source... Go to PubMed...
  4. Haynes RB, Taylor DW, Sachett DL. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979.
  5. Češková E, Přikryl R, Kašpárek T, Kučerová H. Nedostatek náhledu a nonkompliance a jejich vzájemný vztah u schizofrenie. Česká a slovenská psychiatrie 2007; 7: 336-340.
  6. Lacro J, Dunn L, Dolder C, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-908. Go to original source... Go to PubMed...
  7. Dolder C, Lacro J, Jeste D. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003; 65: 156-162. Go to original source... Go to PubMed...
  8. Perkins D. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128. Go to original source... Go to PubMed...
  9. Weiss K, Smith T, Hull J, et al. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002; 28: 341-349. Go to original source... Go to PubMed...
  10. Kampman O, Illi A, Poutanen P, Leinonen E. Four-year outcome in non-compliant schizophrenia patients treated with or without home-based ambulatory outpatient care. Eur Psychiatry 2003; 18: 1-5. Go to original source... Go to PubMed...
  11. Sajatovic M, Rosch D, Sivec H, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002; 53: 1319-1321. Go to original source... Go to PubMed...
  12. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 150: 1653-1664. Go to original source... Go to PubMed...
  13. Španiel F, Vohlídka P, Hrdlička J, et al. ITAREPS: information technology aided relapse prevention programme in schizofrenia. Schizophr Res 2008; 98: 312-317. Go to original source... Go to PubMed...
  14. Awad AG. Antipsychotic Medications: Compliance and Attitudes Towards Treatment. Curr Opin Psychiatry 2004; 17(2): 75-80. Go to original source...
  15. O'Donnell C, Donohoe G, Sharkey N, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ 2003; 327: 834-838. Go to original source... Go to PubMed...
  16. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868-2879. Erratum: JAMA 2003; 289: 3242. Go to original source...
  17. Voruganti LNP, Cortese L, Oyewumi L, et al. Switching from conventional to novel antipsychotic drugs: results of prospective naturalistic study. Schizophr Res 2002; 57: 201-208. Go to original source... Go to PubMed...
  18. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state medicaid program. Psychiatr Serv 2003; 54: 719-723. Go to original source... Go to PubMed...
  19. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007; 68(2): e04. Go to original source... Go to PubMed...
  20. Fleischhacker W, Keet I, Kahn R. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophrenia Research 2007; 78(2): 147-156. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.